• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Sarepta Therapeutics Looks Ready to Break Out to the Upside

Here's how to play this stock.
By BRUCE KAMICH
Jul 12, 2019 | 12:57 PM EDT
Stocks quotes in this article: SRPT

During Thursday night's Lightning Round one caller inquired about Sarepta Therapeutics Inc. (SRPT) : "I think they're brilliant. I think the doubters are wrong," Jim Cramer replied.

Let's check out the charts and indicators.

In the daily bar chart of SRPT, below, we can see an "interesting pattern." SRPT has been in a long sideways consolidation pattern, but look closer. Draw an imaginary line across $120 or $110 -- notice all the dips into that area? Now imagine a line across $155 or so. There are only a few tests of that line. The sense I get from this pattern is that SRPT has been bought a lot more than sold.

The moving averages are little help in the analysis. The On-Balance-Volume (OBV) line has been uneven but does show a rising pattern from April. The Moving Average Convergence Divergence (MACD) oscillator is above the zero line and rising.

In the three-year weekly bar chart of SRPT, below, we can see an impressive rise from around $30 back in 2016/2017 to over $160 in 2018. This rally has been followed by a large sideways consolidation pattern. SRPT is above the bottoming 40-week moving average line.

The weekly OBV line has held relatively stable during the sideways trend suggesting that investors did not liquidate positions. The weekly MACD oscillator has just turned up above the zero line for an outright go long signal.

In this Point and Figure chart of SRPT, below, we can see an upside price target of $177.

Bottom-line strategy: SRPT looks ready for an upside breakout. Traders could go long at current levels risking a close below $140. The $175 area is our first price target.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Healthcare | Science | Mad Money

More from Stocks

Will the Bears Pass or Flunk a Retest?

Helene Meisler
Aug 9, 2022 6:00 AM EDT

Let's check all the boxes on market sentiment, breadth, positive divergences and index levels.

There Are Interesting Things Happening Beneath the Surface of This Market

James "Rev Shark" DePorre
Aug 8, 2022 4:32 PM EDT

Look for more positioning on Tuesday ahead of two important economic reports.

Can Rhythm Pharmaceuticals Keep Up This Tempo?

Bruce Kamich
Aug 8, 2022 3:01 PM EDT

The stock has surged amid an analyst upgrade.

What AIG's Charts Say About the Stock Ahead of Earnings

Bruce Kamich
Aug 8, 2022 2:03 PM EDT

The stock just tested the underside of the declining 50-day moving average.

Solar Firm Sunrun Continues to Run on the Upside

Bruce Kamich
Aug 8, 2022 1:24 PM EDT

Here's what the longer-term picture looks like.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • 03:51 PM EDT REAL MONEY

    AMD Second-Quarter Earnings Live Blog

    Real Money's Eric Jhonsa covers 's second-quarte...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login